CSL Limited (ASX: CSL) and this ASX 200 share could be among the best options for Australian investors to choose from right now…
The post 2 of the best ASX 200 shares according to analysts appeared first on The Motley Fool Australia. –
The Australian share market is home to a good number of high quality companies with strong business models.
Among the best of them are arguably the shares listed below. Here’s why these ASX shares could be quality options for investors right now:
The first ASX share to consider is CSL. While this leading biotechnology company would be a top option at most times, now appears to be a particularly good time to make an investment. This is due to a recent and sharp pullback in the CSL share price.
This weakness has been driven by plasma collection headwinds caused by the pandemic. The good news is that increased demand for flu vaccines from the Seqirus business looks set to offset much or even all of this. And with plasma collections expected to improve once the pandemic passes, CSL appears well-placed for growth once conditions ease.
This should be supported by its lucrative R&D pipeline, which is filled with a number of potentially lucrative therapies that could be launched in the not so distant future. One of those is Clazakizumab. It is a humanised recombinant monoclonal antibody targeting interleukin-6 for the potential treatment of chronic active antibody-mediated rejection. This is the leading cause of long-term rejection in kidney transplant recipients. If successful, peak sales are estimated to be US$5.4 billion per annum.
Citi currently has a buy rating and $310 price target on its shares.
Another option to consider is Xero. This cloud-based business and accounting platform provider has been growing strongly over the last few years.
This has been driven by the shift to the cloud, its international expansion, acquisitions, increasing revenue per user, and its evolution into a full service solution.
The good news is that these same trends look set to underpin further strong growth over the next decade. This should be supported by its burgeoning app ecosystem, which Goldman Sachs is incredibly positive on.
According to a note, the broker estimates that Xero has a core total addressable market (TAM) of NZ$14 billion across its key markets. However, if it can successfully broaden and monetise its app ecosystem and expand into new geographies, Goldman believe it would open a further NZ$62 billion in TAM. As a result, it believes Xero has “a multi-decade runway for strong revenue growth.”
Goldman Sachs has a buy rating and $153.00 price target on its shares.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why the CSL (ASX:CSL) share price has rebounded 13% since March
- AUSSIE-FIRST: How to buy a fraction of an ASX share
- 2 five-star ASX 200 shares that are rated very highly
- Aussie dollar shoots higher! Here are some ASX winners
- CSL (ASX:CSL) share price wobbles on plasma and vaccine update
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Xero. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post 2 of the best ASX 200 shares according to analysts appeared first on The Motley Fool Australia.